58
1
20
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T7900 |
BAY-474
|
c-Met/HGFR | Tyrosine Kinase/Adaptors |
BAY-474 是酪氨酸蛋白激酶 c-MET 抑制剂,能够用于表观遗传学探针。 | |||
T6094 |
MK-2461
MK2461 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
MK-2461 是 ATP 竞争性的 c-Met 抑制剂, 平均 IC50 值为 2.5 nM。 | |||
T2293 |
SGX-523
|
Raf; p38 MAPK; c-Met/HGFR; Bcr-Abl | Angiogenesis; Cytoskeletal Signaling; MAPK; Tyrosine Kinase/Adaptors |
SGX523 是选择性的和 ATP 竞争性的MET 抑制剂 (IC50:4 nM)。它对 MET 的选择性其它他蛋白激酶高 1000 倍。它具有抗肿瘤特性。 | |||
T6095 |
JNJ-38877605
|
c-Met/HGFR | Tyrosine Kinase/Adaptors |
JNJ38877605 是 ATP 竞争性 c-Met 抑制剂 (IC50:4 nM),对c-Met 的抑制性比对其它 200 种酪氨酸和丝氨酸-苏氨酸激酶的抑制性高 600 倍。 | |||
T10655 |
c-Met inhibitor 1
3-[(2-甲基-2H-吲唑-5-基)硫基]-6-(1-甲基-1H-吡唑-4-基)-1,2,4-三唑并[4,3-B]哒嗪 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
c-Met inhibitor 1 是一种 c-Met 受体信号通路抑制剂,可用于癌症的治疗,包括胶质母细胞瘤、胃癌和胰腺癌。 | |||
T5349 |
SCR-1481B1
麦他替尼胺丁三醇,c-Met inhibitor 2 |
VEGFR; c-Met/HGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
SCR-1481B1 (c-Met inhibitor 2) 能够作用于依赖 Met 激活的癌症,对 VEGFR 具有抑制作用。 | |||
T2680 |
NVP-BVU972
|
c-Met/HGFR | Tyrosine Kinase/Adaptors |
NVP-BVU972 是 Met 选择性抑制剂 (IC50:14 nM) ,它对其它的激酶抑制性较低。 | |||
T2419 |
BMS-794833
|
VEGFR; c-Met/HGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
BMS794833 是一种 VEGFR2 和 Met 的抑制剂,它们的 IC50值分别为 15 和 1.7 nM。 | |||
T6154 |
SU11274
Met Kinase Inhibitor,PKI-SU11274 |
Apoptosis; VEGFR; FGFR; c-Met/HGFR; CDK; Autophagy | Angiogenesis; Apoptosis; Autophagy; Cell Cycle/Checkpoint; Tyrosine Kinase/Adaptors |
SU11274 (Met Kinase Inhibitor) 是一种选择性的 Met 抑制剂,IC50值为 10 nM。它对 PGDFRβ,EGFR 或 Tie2 没有抑制作用。 | |||
T3274 |
S49076
|
FGFR; c-Met/HGFR; TAM Receptor | Angiogenesis; Tyrosine Kinase/Adaptors |
S49076 是一种新型 MET、AXL/MER 和 FGFR1/2/3 高效抑制剂,IC50<20 nM。 | |||
T6117 |
Tivantinib
ARQ 197 |
Apoptosis; c-Met/HGFR | Apoptosis; Tyrosine Kinase/Adaptors |
Tivantinib (ARQ 197) 是一种高选择性c-Met 酪氨酸激酶抑制剂,Ki 为 355 nM。 | |||
T11162 |
EGFR-IN-8
|
EGFR; c-Met/HGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
EGFR-IN-8 是 EGFR 和 c-Met 的双重抑制剂。 EGFR-IN-8可用于靶向 EGFR TKI 耐药的 NSCLC 的研究。 | |||
T6378 |
AMG-458
AMG 458 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
AMG-458 是一种口服有活力的c-Met 选择性抑制剂,其对人和小鼠的Ki 分别为 1.2 nM 和 2.0 nM。 | |||
T37596 |
Terevalefim
|
c-Met/HGFR | Tyrosine Kinase/Adaptors |
Terevalefim 是干细胞生长因子的一种类似物,对c-Met 受体有选择性激活作用。 | |||
T6128 |
PHA-665752
PHA 665752,PHA665752 |
Apoptosis; VEGFR; FGFR; c-Met/HGFR; Bcr-Abl; Autophagy | Angiogenesis; Apoptosis; Autophagy; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
PHA-665752 是一种选择性的 ATP 竞争活性位点 c-Met 激酶抑制剂,Ki 为 4 nM,IC50为 9 nM。它对 c-Met 的选择性比一组不同的酪氨酸和丝氨酸苏氨酸激酶高 50 倍。它诱导细胞凋亡和细胞周期阻滞,具有细胞还原性抗肿瘤活性。 | |||
T6260 |
AMG-208
AMG 208 |
P450; c-Met/HGFR | Metabolism; Tyrosine Kinase/Adaptors |
AMG-208 是一种选择性的、口服有活性的c-Met/RON 双抑制剂,对c-Met 的IC50为 9 nM。他也是CYP3A4抑制剂(IC50:32 μM)。它具有抗癌作用。 | |||
TQ0041 |
Ningetinib Tosylate
|
VEGFR; c-Met/HGFR; TAM Receptor | Angiogenesis; Tyrosine Kinase/Adaptors |
Ningetinib Tosylate 是口服具有活力的、小分子酪氨酸激酶抑制剂,能够抑制 c-Met (IC50:6.7 nM),VEGFR2 (IC50:1.9 nM) 和 Axl (IC50<1.0 nM)。 | |||
T5478 |
SRI 31215 TFA
SRI 31215 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
SRI 31215 TFA 是 matriptase、hepsin、肝细胞生长因子激活剂(HGFA)的三重抑制剂,IC50值分别为 0.69 μM、0.65 μM、0.3 μM。它能够阻断 pro-HGF 的活化,模拟 HAI-1/2 的活性。 | |||
T5467 |
SAR125844
SAR125884 |
Apoptosis; c-Met/HGFR | Apoptosis; Tyrosine Kinase/Adaptors |
SAR125844 是高度选择性可逆ATP 竞争性的MET 受体酪氨酸激酶抑制剂,其IC50值为4.2 nM。能抑制细胞中MET 的自磷酸化。 | |||
T9123 |
DS-1205
|
TAM Receptor | Tyrosine Kinase/Adaptors |
DS-1205b free base 是有效的AXL 激酶选择性抑制剂,IC50为 1.3 nM。它对MER,MET 和TRKA 也有抑制作用,IC50分别为 63、104 和 407 nM。 它可以抑制细胞迁移和肿瘤生长。 | |||
T13194 |
CSF1R-IN-2
|
c-Fms; c-Met/HGFR; Src | Angiogenesis; Tyrosine Kinase/Adaptors |
CSF1R-IN-2 是一种口服具有活力的、有效的 SRC,MET 和 c-FMS 抑制剂,它们的 IC50 值分别为 0.12 nM,0.14 nM 和 0.76 nM。 | |||
T15617 |
JNJ-38877618
OMO-1 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
JNJ-38877618 (OMO-1)是一种口服有活性的 Met 激酶选择性抑制剂,其对野生型和突变体的 IC50值分别为2和3 nM。 | |||
T6907 |
NPS-1034
NPS1034,NPS 1034 |
Apoptosis; c-Met/HGFR; TAM Receptor | Apoptosis; Tyrosine Kinase/Adaptors |
NPS-1034 是一种AXL 和MET 的双重抑制剂,其IC50值分别为 10.3 和 48 nM。 | |||
T4332 |
c-Kit-IN-1
PDGFR inhibitor 1,DCC-2618 |
c-Met/HGFR; c-Kit | Tyrosine Kinase/Adaptors |
c-Kit-IN-1 (DCC-2618) 是c-Kit 和c-Met 抑制剂(IC50<200 nM)。 | |||
T2496 |
(Z)-Semaxinib
SU5416 |
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
(Z)-Semaxinib (SU5416) 是一种有效的选择性 VEGFR(Flk-1/KDR) 抑制剂 (IC50: 1.23 μM),对 VEGFR 的选择性是 PDGFRβ 的 20 倍,对 FGFR、InsR 和 EGFR 没有抑制作用。 Semaxanib 是一种具有潜在抗肿瘤活性的喹诺酮衍生物。 | |||
T8409 |
SYN1143
RON-IN-1,AMG-1 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
SYN1143 (AMG-1) 是人 RON 和 c-Met 的有效抑制剂。体外激酶测定表明 SYN1143 对人 RON 和 c-Met 的 IC50 分别为 9 和 4 nmol/L。 | |||
T3209 |
AMG-337
AMG337 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
AMG-337 是有效的、ATP 竞争性的、高度选择性的MET 激酶抑制剂,IC50 < 5 nM。 | |||
T2676 |
PF-04217903
|
c-Met/HGFR | Tyrosine Kinase/Adaptors |
PF04217903 是一种高效的、 ATP 竞争性的c-Met 激酶抑制剂(Ki=4.8 nM),相对于 208 个激酶,PF04217903 显示出 1000 倍以上的选择性。它抗血管生成作用。 | |||
T5414 |
Glumetinib
SCC244 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
Glumetinib (SCC244) 是一种高选择性、ATP 竞争性的、口服具有活力的 c-Met 抑制剂。它对 c-Met 的选择性超过 312 种激酶,包括 c-Met 家族成员 RON 和高度同源的激酶 Axl、Mer、TyrO3。它具有抗肿瘤作用。 | |||
T2699 |
BMS 777607
BMS777607,BMS-777607,BMS 817378 |
c-Met/HGFR; TAM Receptor | Tyrosine Kinase/Adaptors |
BMS 777607 (BMS 817378) 是 Met-related 抑制剂,能够抑制 c-Met (IC50:3.9 nM),Axl (IC50:1.1 nM),Ron (IC50:1.8 nM) 和 Tyro3 (IC50:4.3 nM) 的活性。 | |||
T6517 |
Golvatinib
E-7050,戈伐替尼 |
VEGFR; c-Met/HGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Golvatinib (E-7050) 是一种 c-Met (IC50:14 nM) 和 VEGFR2 (IC50:16 nM) 的双重抑制剂。 | |||
TQ0219 |
MK-8033
|
c-Met/HGFR | Tyrosine Kinase/Adaptors |
MK-8033 是一种新型ATP 竞争性c-Met/Ron 双重抑制剂,对野生型c-Met 的IC50=1 nM,对c-Met N1100Y 的IC50=2.0 nM。 | |||
T4426 |
CEP-40783
CEP 40783,RXDX-106 |
c-Met/HGFR; TAM Receptor | Tyrosine Kinase/Adaptors |
CEP-40783 (RXDX-106) 是一种有口服活性的,高效的,选择性的 AXL (IC50:7 nM) 和 c-Met (IC50:12 nM) 抑制剂。 | |||
TQ0021 |
Ningetinib
CT-053,CT053PTSA,宁格替尼 |
VEGFR; c-Met/HGFR; TAM Receptor | Angiogenesis; Tyrosine Kinase/Adaptors |
Ningetinib (CT-053) 是口服具有活力的、小分子酪氨酸激酶抑制剂,能够抑制 c-Met (IC50:6.7 nM),VEGFR2 (IC50:1.9 nM) 和 Axl (IC50<1.0 nM)。 | |||
T10585 |
Bozitinib
CBT-101,PLB-1001 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
Bozitinib (PLB-1001) 是一种可透过血脑屏障的、高效的、选择性的的、 ATP 竞争性的小分子 c-MET 激酶抑制剂,能够与酪氨酸激酶超家族的常规 ATP 结合口袋结合。 | |||
T9052 |
XL092
CL-092,JUN04542 |
VEGFR; c-Met/HGFR; TAM Receptor | Angiogenesis; Tyrosine Kinase/Adaptors |
XL092 (JUN04542) 是一种ATP 竞争性的、口服有效的多受体酪氨酸激酶 (RTKs) 抑制剂,在细胞分析中的MET (IC50:15 nM)、VEGFR2 (IC50:1.6 nM)、AXL (IC50:3.4 nM) 和 MER (IC50:7.2 nM)。它具有抗肿瘤作用,具有用于研究激酶依赖性疾病的潜力。 | |||
T3455 |
Merestinib
LY2801653 |
Discoidin Domain Receptor (DDR); FLT; c-Met/HGFR; ROS; ROS Kinase | Angiogenesis; Immunology/Inflammation; Tyrosine Kinase/Adaptors |
Merestinib (LY2801653) 是一种有效的口服生物可利用的具有抗肿瘤活性的c-Met 抑制剂。 | |||
T8825 |
Capmatinib 2HCl.H2O
INCB28060 2HCl.H2O,INC-280 2HCl.H2O,NVP-INC280 2HCl.H2O |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) 是一种具有潜在抗肿瘤活性的原癌基因 c-Met (HGFR) 的口服生物可利用抑制剂。 | |||
T2054 |
Altiratinib
DCC-2701 |
VEGFR; Tie-2; FLT; Trk receptor; c-Met/HGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Altiratinib (DCC-2701) 是一种多靶点激酶抑制剂,能够抑制 MET (IC50:2.7 nM),TIE2 (IC50:8 nM),VEGFR2 (IC50:9.2 nM),FLT3 (IC50:9.3 nM),Trk1 (IC50:0.85 nM),Trk2 (IC50:4.6 nM) 和 Trk3 (IC50:0.83 nM)。 | |||
TQ0210 |
Savolitinib
AZD-6094,Volitinib,沃利替尼,赛沃替尼,HMPL-504 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
Savolitinib (Volitinib) 是一种高效选择性、口服生物利用度c-Met 抑制剂,能够抑制 c-Met (IC50:5 nM)和 p-Met (IC50:3 nM)。它以 ATP 竞争的方式选择性结合并抑制 c-Met 的激活,破坏 c-Met 信号转导途径,具有抗肿瘤作用。 | |||
T1661 |
Crizotinib
PF-02341066,克唑替尼 |
c-Met/HGFR; ROS; ALK; Autophagy; ROS Kinase | Angiogenesis; Autophagy; Immunology/Inflammation; Tyrosine Kinase/Adaptors |
Crizotinib (PF-02341066) 是一种小分子酪氨酸激酶抑制剂,抑制 c-MET 和 ALK 受体 (IC50=8/20 nM),具有 ATP 竞争性,也可以抑制 ROS1。Crizotinib 具有抗肿瘤活性,可以抑制肿瘤生长。 | |||
T2516 |
Amuvatinib
MP470,HPK 56 |
Apoptosis; FLT; c-Met/HGFR; c-RET; DNA/RNA Synthesis; PDGFR; c-Kit | Angiogenesis; Apoptosis; Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Tyrosine Kinase/Adaptors |
Amuvatinib (MP470) 是一种多靶点酪氨酸激酶抑制剂,对突变 c-Kit,PDGFRα,Flt3,c-Met 和 c-Ret 具有活性。它还是一种 DNA 修复抑制剂,靶向蛋白 DNA 修复 RAD51,从而破坏 DNA 损伤修复,具有抗肿瘤活性。 | |||
T1963 |
Capmatinib
NVP-INC280,INC-280,卡马替尼,INCB28060 |
Apoptosis; c-Met/HGFR | Apoptosis; Tyrosine Kinase/Adaptors |
Capmatinib (INCB28060) 是一种具有口服活性的,选择性的,ATP 竞争性的c-Met 激酶抑制剂,IC50值为0.13 nM。它有效抑制 c-Met 依赖性肿瘤细胞的增殖和迁移,可诱导细胞凋亡,有抗肿瘤活性。 | |||
T6351 |
MGCD-265 analog
MGCD-265,Glesatinib |
Apoptosis; VEGFR; c-Met/HGFR | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
MGCD-265 analog (Glesatinib) 是一种口服生物可利用的多靶点酪氨酸激酶抑制剂,具有抗肿瘤活性,对 c-Met 和 VEGFR2 的 IC50 分别为 29 nM 和 10 nM。 | |||
T3550 |
X-376
Ensartinib,X-396,恩沙替尼 |
c-Met/HGFR; ALK | Angiogenesis; Tyrosine Kinase/Adaptors |
X-376 (Ensartinib) 是一种有效的ALK 抑制剂,对许多具有crizotinib 抗性的ALK 突变型和中枢神经系统转移具有高活性。它能有效地抑制野生型ALK 和ALK 变体(F1174, C1156Y, L1196M, S1206R, T1151和G1202R 突变型),IC50小于4 nM。 | |||
T17184 |
Tyrosine kinase inhibitor
|
c-Met/HGFR; Tyrosine Kinases | Tyrosine Kinase/Adaptors |
Tyrosine kinase inhibitor 是酪氨酸激酶的有效抑制剂。 | |||
T8416 |
Capmatinib xHCl
INCB28060,Capmatinib hydrochloride(free base),INC280 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
Capmatinib xHCl (INCB28060) 是一种有效的、口服活性的、选择性的和 ATP 竞争性 c-Met 激酶抑制剂,有效地阻断体外激酶活性 (IC50 = 0.13 nM) 以及在细胞中的组成型或 HGF 刺激活性(IC50 值范围从 0.3 到1.1纳米)。 | |||
T22324 |
Ensartinib hydrochloride
Ensartinib dihydrochloride,X-396 dihydrochloride |
Others; Trk receptor; c-Met/HGFR; ALK | Angiogenesis; Others; Tyrosine Kinase/Adaptors |
Ensartinib hydrochloride (X-396 dihydrochloride) 是双重的 ALK/MET 抑制剂,IC50分别 <0.4 nM 和 0.74 nM。 | |||
T8399 |
Crizotinib hydrochloride
克里唑替尼盐酸,PF-02341066 hydrochloride |
c-Met/HGFR; ROS; ALK; Autophagy; ROS Kinase | Angiogenesis; Autophagy; Immunology/Inflammation; Tyrosine Kinase/Adaptors |
Crizotinib hydrochloride (PF-02341066 hydrochloride) 是一种可口服的,具有选择性的 ATP 竞争性双 ALK 和 c-Met 抑制剂。它也是 ROS 原癌基因 1 抑制剂,可抑制肿瘤生长。在细胞的实验中,它抑制 NPM-ALK 的酪氨酸磷酸化和 c-Met 的酪氨酸磷酸化。 | |||
T3113 |
Foretinib
GSK089,EXEL-2880,GSK1363089,XL880 |
VEGFR; Tie-2; c-Met/HGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Foretinib (GSK1363089) 是多靶点酪氨酸激酶抑制剂,能够抑制 Met (IC50:0.4 nM) 和 KDR (IC50:0.9 nM)。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T13108 |
Pamufetinib
H2OL3Q4XRD,4-(2-Fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide,TAS-115 |
VEGFR; c-Met/HGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Pamufetinib (TAS-115) 是VEGFR 和c-Met/HGFR 抑制剂,能够抑制 rVEGFR2 (IC50:30 nM)和 rMET (IC50:32 nM)的活性。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-01896 |
HGFR/c-Met Protein, Mouse, Recombinant (His)
MET proto-oncogene, receptor tyro... |
Mouse | HEK293 Cells |
HGFR/c-Met Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 102 kDa and the accession number is EDL13881.1. | |||
TMPY-01296 |
HGFR/c-Met Protein, Human, Recombinant (His)
AUTS9,MET proto-oncogene, recepto... |
Human | HEK293 Cells |
HGFR/c-Met Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 103 kDa and the accession number is A0A024R759. | |||
TMPY-01895 |
HGFR/c-Met Protein, Mouse, Recombinant (hFc)
c-Met,AI838057,MET proto-onc<... |
Mouse | HEK293 Cells |
HGFR/c-Met Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 128 kDa and the accession number is A4FUV6. | |||
TMPY-05441 |
HGFR/c-Met Protein, Human, Recombinant (hFc)
HGFR,DFNB97,RCCP2,AUTS9,c |
Human | HEK293 Cells |
HGFR/c-Met Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 128.4 kDa and the accession number is A0A024R759. | |||
TMPY-00718 |
HGFR/c-Met Protein, Human, Recombinant (His & hFc)
DFNB97,RCCP2,AUTS9,MET proto-on |
Human | HEK293 Cells |
HGFR/c-Met Protein, Human, Recombinant (His & hFc) is expressed in HEK293 mammalian cells with His and hFc tag. The predicted molecular weight is 129.5 kDa and the accession number is A0A024R759. | |||
TMPY-05607 |
HGFR/c-Met Protein, Human, Recombinant (His & Avi), Biotinylated
MET proto-oncogene, receptor tyro... |
Human | HEK293 Cells |
HGFR/c-Met Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with His and Avi tag. The predicted molecular weight is 104.9 kDa and the accession number is A0A024R759. | |||
TMPY-04379 |
HGFR/c-Met Protein, Human, Recombinant (aa 956-1390, His & GST)
MET proto-oncogene, receptor tyro... |
Human | Baculovirus Insect Cells |
HGFR/c-Met Protein, Human, Recombinant (aa 956-1390, His & GST) is expressed in Baculovirus insect cells with His and GST tag. The predicted molecular weight is 76.8 kDa and the accession number is P08581-1. | |||
TMPY-00548 |
HGFR/c-Met Protein, Cynomolgus, Rhesus, Recombinant (His)
MET proto-oncogene, receptor tyro... |
Cynomolgus,Rhesus | HEK293 Cells |
HGFR/c-Met Protein, Cynomolgus, Rhesus, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 103.1 kDa and the accession number is G7MM61. | |||
TMPY-02068 |
HGFR/c-Met Protein, Canine, Recombinant (His)
MET proto-oncogene, receptor tyro... |
Canine | HEK293 Cells |
HGFR/c-Met Protein, Canine, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 103 kDa and the accession number is Q75ZY9. | |||
TMPK-00499 |
HGFR/c-Met Protein, Cynomolgus, Recombinant (His)
MET,oncogene MET,cME... |
Cynomolgus | HEK293 Cells |
c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene.The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. HGFR/c-Met ... | |||
TMPY-00634 |
HGFR/c-Met Protein, Cynomolgus, Rhesus, Recombinant
MET proto-oncogene, receptor tyro... |
Cynomolgus,Rhesus | HEK293 Cells |
HGFR/c-Met Protein, Cynomolgus, Rhesus, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 102.3 kDa and the accession number is G7MM61. | |||
TMPY-06657 |
HGFR/c-Met Protein, Rat, Recombinant (His)
MET proto-oncogene, receptor tyro... |
Rat | HEK293 Cells |
HGFR/c-Met Protein, Rat, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 102.53 kDa and the accession number is XP_006236191.1. | |||
TMPY-03581 |
HGFR/c-Met Protein, Rat, Recombinant (hFc)
MET proto-oncogene, receptor tyro... |
Rat | HEK293 Cells |
HGFR/c-Met Protein, Rat, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 128.1 kDa and the accession number is Q2IBC7. | |||
TMPY-00546 |
HGFR/c-Met Protein, Cynomolgus, Rhesus, Recombinant (hFc)
MET proto-oncogene, receptor tyro... |
Cynomolgus,Rhesus | HEK293 Cells |
HGFR/c-Met Protein, Cynomolgus, Rhesus, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 128.3 kDa and the accession number is G7MM61. | |||
TMPK-00457 |
HGFR/c-Met Protein, Human, Recombinant (His & Avi)
cMET,Met (c-Met... |
Human | HEK293 Cells |
c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene.The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. HGFR/c-Met ... | |||
TMPY-06278 |
HGFR/c-Met Protein, Cynomolgus, Rhesus, Recombinant (His), Biotinylated
MET proto-oncogene, receptor tyro... |
Cynomolgus,Rhesus | HEK293 Cells |
HGFR/c-Met Protein, Cynomolgus, Rhesus, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 103.1 kDa and the accession number is NP_001162100.2. | |||
TMPJ-00415 |
HGFR/c-Met Protein, Human, Recombinant (aa 25-932, His & Avi), Biotinylated
SF receptor,HGF receptor,Scatter ... |
Human | HEK293 Cells |
Hepatocyte growth factor receptor (HGF R) is a glycosylated receptor tyrosine kinase that plays a central role in epithelial morphogenesis and cancer development. HGF R is synthesized as a single chain precursor which undergoes cotranslational proteolytic cleavage. Mature HGF R is a disulfide-linked dimer composed of a 50 kDa extracellular α chain and a 145 kDa transmembrane β chain. Proteolysis and alternate splicing generate additional forms of human HGF R which either lack of the kinase domai... | |||
TMPK-01450 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01456 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2A,K-RAS2B... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01451 |
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-RAS,KRAS,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |